D. Vickery - Oncology Clinical Development, Merck & Co., Inc. - Rahway

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Belzutifan Versus Everolimus for Advanced Renal-Cell Carcinoma

T. K. Choueiri,T. Powles,K. Peltola,G. de Velasco,M. Burotto, C. Suarez,P. Ghatalia,R. Iacovelli,E. T. Lam,E. Verzoni,M. Gumus, W. M. Stadler, C. Kollmannsberger,B. Melichar,B. Venugopal, M. Gross-Goupil,A. Poprach, M. De Santis,F. A. Schutz, S. H. Park, D. A. Nosov,C. Porta,J. L. Lee, X. Garcia-del-Muro,E. Biscaldi,R. Manneh Kopp, M. Oya, L. He, A. Wang,R. F. Perini,D. Vickery,L. Albiges,B. Rini

NEW ENGLAND JOURNAL OF MEDICINEno. 8 (2024): 710-721

引用0浏览0引用

LBA74 Final Analysis of the Phase III LITESPARK-005 Study of Belzutifan Versus Everolimus in Participants (pts) with Previously Treated Advanced Clear Cell Renal Cell Carcinoma (Ccrcc)

B.I. Rini,C. Suarez Rodriguez, L. Albiges, K. Jalkanen,G.A. De Velasco Oria,M. Burotto,P. Ghatalia,R. Iacovelli,E.T. Lam,E. Verzoni, M. Gumus, W. Stadler,C.K. Kollmannsberger, B. Melichar, B. Venugopal, J. Lin, R. Perini,D. Vickery, T.K. Choueiri,T.B. Powles

Annals of Oncology (2024)

引用0浏览0引用

LBA87 Phase II LITESPARK-003 Study of Belzutifan in Combination with Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (Ccrcc)

T.K. Choueiri, T. Bauer,J.R. Merchan,D.F. McDermott,R. Figlin,E. Arrowsmith,M.D. Michaelson,E. Heath, A.A. D'Souza, S. Zhao,L. Mhamdi,R. Perini,D. Vickery,S. Tykodi

Annals of Oncology (2023): S1328-S1329

引用0浏览0引用

1447O Phase II Study of Belzutifan Plus Cabozantinib As First-Line Treatment of Advanced Renal Cell Carcinoma (RCC): Cohort 1 of LITESPARK-003

T. K. Choueiri, T. Bauer,J. Merchan, R. Figlin, A. Roy, R. Perini,D. Vickery,E. Arrowsmith

Annals of oncology (2022): S1204-S1204

引用0浏览0引用

Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003

T. K. Choueiri,T. Bauer,J. Merchan,R. Figlin,A. Roy,R. Perini,D. Vickery,E. Arrowsmith

ANNALS OF ONCOLOGY（2022）

引用4浏览0引用

Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003

D. F. McDermott,T. K. Choueiri,S. Tykodi,J. Merchan,A. Roy,R. Perini,D. Vickery,T. Bauer

ANNALS OF ONCOLOGY（2022）

引用4浏览0引用

Phase II Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2 Α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (Ccrcc)

D. F. McDermott,T. K. Choueiri,T. M. Bauer,E. Arrowsmith,A. Roy,R. Perini,D. Vickery,S. S. Tykodi

Journal of clinical oncology（2020）

引用1浏览0引用

CheckMate 817: Safety of Flat-Dose Nivolumab (nivo) Plus Weight-Based Ipilimumab (ipi) for the First Lie (1 L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

JR Fischer,L Paz-Ares,L Urban,C Audigier-Valette,F Grossi,K Jao,JS Aucoin,H Linardou, E Vladimirovna Poddubskaya, A Cuiioni Fontecedro,HJM Groen,K Vermaelen,M Bourhaba,D Kowalski, R Narayana Pillai,DR Spigel,S Ahmed, W Hu,D Vickery,J Fiore,N Ready

60 Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e V Pneumologie（2019）

引用0浏览0引用

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC

Luis Paz-Ares,L. Urban,C. Audigier-Valette,F. Grossi,K. Jao, J. Aucoin,H. Linardou, E. Vladimirovna Poddubskaya,J. Fischer,A. Curioni Fontecedro,H. Groen,K. Vermaelen,M. Bourhaba,D. Kowalski,R. Pillai,David R. Spigel,S. Ahmed,W. Hu,D. Vickery,J. Fiore,Neal Ready

JOURNAL OF THORACIC ONCOLOGY（2018）

引用11浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn